PD-L1 (SP263) Assay, VENTANA

Skip to Content


Skip over Generic Navigation

  • Select your country:
DIAGNOSTICS F. Hoffmann-La Roche Ltd

VENTANA PD-L1 (SP263) Assay

VENTANA PD-L1 (SP263) Assay, urothelial carcinoma
Catalog Number:740-4907
Ordering Code:07208162001
Quantity:50 tests
Controls:Placenta
Clone Name:SP263
Species:Rabbit
Localization:Membranous and/or Cytoplasmic Staining
Regulatory Status:IVD

VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit on a VENTANA BenchMark ULTRA instrument.

PD-L1 status is determined by the percentage of tumor cells with any membrane staining above background or by the percentage of tumor-associated immune cells with staining (IC+) at any intensity above background. The percent of tumor area occupied by any tumor-associated immune cells (Immune Cells Present, ICP) is used to determine IC+, which is the percent area of ICP exhibiting PD-L1 positive immune cell staining. PD-L1 status is considered High if any of the following are met:

  • ≥ 25% of tumor cells exhibit membrane staining; or,
  • ICP > 1% and IC+ ≥ 25%; or,
  • ICP = 1% and IC+ = 100%

PD-L1 High status as determined by VENTANA PD-L1 (SP263) Assay was associated with increased objective response rate (ORR) in a single arm study of IMFINZI™ (durvalumab).

This antibody is intended for in vitro diagnostic (IVD) use.


Health Care Provider Notice
X
This website is intended for healthcare professionals only.

The content on this website is intended for healthcare professionals only. Information intended for the general public can be found on Roche.com. Please confirm that you are a medical professional before accessing the content of this website.

Yes, I hereby certify that I am a healthcare professional. Continue
Third-Party Link Disclosure
X
Disclosure for Links to Third-Party Websites

You are now leaving the Roche website. The site you are about to visit is operated by third-parties. The link to this site neither makes nor implies any representation or warranty for any products or services offered on a third-party site and is intended only to enable convenient access to the third-party site and for no other purpose.

Continue